ipilimumab
ipilimumab
Overview
Ipilimumab is a monoclonal antibody used in cancer immunotherapy. It targets cytotoxic T-lymphocyte associated protein 4 (CTLA-4), an immune checkpoint receptor that normally dampens T-cell activation. By blocking CTLA-4, ipilimumab enhances antitumor immune responses and can promote cytotoxic T cell activity against malignant cells. It is therefore classified as an immune checkpoint inhibitor and is used primarily in combination regimens rather than as a conventional cytotoxic therapy.
Clinically, ipilimumab has been studied across multiple solid tumors, including melanoma, renal cell carcinoma, hepatocellular carcinoma, bladder cancer, uveal melanoma, and rare cancers with brain metastases. Recent research continues to evaluate its role in dual checkpoint inhibitor with nivolumab, as well as in combination with local or systemic therapies such as percutaneous hepatic perfusion, BRAF/MEK inhibitors, and (chemo)radiotherapy. These studies reflect its ongoing importance in checkpoint inhibitor and in treatment strategies for metastatic disease, including brain metastases and liver-dominant tumors.
Focus of Latest Publications
Recent publications underscore the expanding role of ipilimumab in combination with nivolumab across diverse malignancies as a dual immune checkpoint inhibitor targeting CTLA-4 and PD-1/PD-L1. Large randomized trials and real-world cohort studies have confirmed clinical benefits in multiple cancer types. The CheckMate 9DW trial demonstrated that nivolumab plus ipilimumab provided superior overall survival, tumor response rates, and quality of life compared with lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma, establishing this regimen as an effective first-line treatment. In neoadjuvant melanoma therapy (PRADO trial), the combination achieved 5-year outcomes of 86% overall survival, 74% relapse-free survival, and 71% event-free survival, with ongoing immune-related adverse events in survivors predominantly consisting of vitiligo and hypothyroidism.
The combination is being actively studied across solid malignancies including metastatic renal cell carcinoma, esophageal squamous cell carcinoma, muscle-invasive bladder cancer (including in cisplatin-ineligible patients), and colorectal cancer. Real-world evidence from multi-institutional cohorts examining ipilimumab plus nivolumab in esophageal squamous cell carcinoma addresses practical efficacy, safety profiles, and host-related biomarkers relevant to immunotherapy response. Clinical prognostic scoring systems are being developed to stratify patient outcomes with this combination; for example, a three-factor clinical score has been created to identify subsets of metastatic renal cell carcinoma patients likely to derive durable disease control from first-line nivolumab plus ipilimumab therapy.
Emerging evidence supports ipilimumab-based combination strategies in rare and ultra-rare cancers, including gestational trophoblastic neoplasia, angiosarcoma, alveolar soft part sarcoma, and neuroendocrine carcinomas, where patients often face limited treatment alternatives. The NCI/SWOG DART trial demonstrated clinically meaningful activity of nivolumab plus ipilimumab across multiple rare cancer histologies without biomarker selection, with some patients achieving durable disease-free survival years after treatment. Treatment approaches are evolving to enhance efficacy: NP-101, a Nigella sativa formulation, combined with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas refractory to chemotherapy achieved 41.7% objective response rate and 10.5-month median overall survival with manageable tolerability. Percutaneous hepatic perfusion combined with ipilimumab and nivolumab is being evaluated in metastatic uveal melanoma to simultaneously address hepatic and extrahepatic disease burden.
Biomarker research continues to refine patient selection for ipilimumab-based therapy. In neoadjuvant melanoma, major pathologic response correlated with high tumor mutational burden, elevated interferon-gamma signature, and PD-L1 expression ≥1%, with combined high expression of these markers yielding 100% major pathologic response and 100% 5-year event-free survival. Exposure-response relationships between ipilimumab and nivolumab are being characterized across tumor types to optimize dosing. Ongoing work is also examining treatment discontinuation strategies; for example, in melanoma brain metastases, outcomes are being assessed following discontinuation within 24 months versus continued treatment. These studies collectively demonstrate that while ipilimumab in combination with nivolumab represents an effective immunotherapeutic approach across diverse malignancies, refinement of patient selection through biomarkers, optimization of dosing and duration, and exploration of synergistic combinations remain key ongoing research priorities.